Priors rates this Uncertain — 50 out of 100, updated weekly. It is genuinely uncertain. On the claim that GLP-1 receptor agonists or tirzepatide can achieve type 2 diabetes remission (HbA1c <6.5% off glucose-lowering medication) in people with short diabetes duration, though at lower rates than bariatric surgery, its four-agent AI review panel weighs 15 primary peer-reviewed studies.
How we got this answer. Priors runs each claim through a panel of four AI agents, each acting as a specialist expert reviewer. They read the published, peer-reviewed studies behind the question, judge how strong, consistent and reliable the evidence is, and turn that judgment into a single rating from 0 to 100 — refreshed every week as new studies appear, so it reflects where the evidence stands today, not a one-off verdict.
The traceable studies behind this rating — and the panel’s single strongest counter-argument to it — are in Priors’ full Type 2 Diabetes Management review.